Jason Krynicki’s Journey with Weight and Eating Disorders

Jason Krynicki vividly remembers how his struggles with obesity made him a target for relentless bullying from a young age. Even now, at 43 and weighing just 127 pounds, those memories linger.

“You try to eat, and your mind reflexively goes back to the comments from 20 years ago,” he reflects, recalling how his appetite and food choices were criticized by peers and even medical professionals.

Krynicki, who works as an insurance coordinator in Brick, NJ, underwent bariatric surgery a decade ago. However, he regained some weight during the pandemic, prompting his doctor to start him on Zepbound, a GLP-1 injection. This led to a significant loss of 80 pounds, although it also brought along other health concerns. Yet, he finds himself fixated on losing even more weight.

With the growing availability of GLP-1s, which suppress appetite, some people prone to eating disorders are more at risk. These medications are surprisingly easy to acquire online, often without proper screening. Many individuals may not meet official criteria for an eating disorder, yet have problematic relationships with food and body image. Experts remain concerned about the lack of information regarding the implications of GLP-1 use among those who binge eat or restrict their diets.

Internal Conflicts and Anorexia Diagnosis

For Krynicki, meals bring a mix of guilt and an awareness that he should probably regain some muscle. “I’ve lost hair,” he admits, feeling dizzy at times due to low blood sugar levels. Despite these struggles, he finds himself weighing in every couple of days.

He’s battling anorexia but is hesitant to stop his monthly injections. “I fear returning to the 267-pound version of myself, who faced numerous health issues and deep self-loathing,” he confesses.

Holding Two Truths

Many patients don’t receive thorough assessments for eating disorders when prescribed GLP-1 drugs, according to psychologist Robyn Pashby. She emphasizes that these medications are legitimate treatments for obesity, yet also acknowledged the cultural pressures surrounding weight and the potential risks of developing eating disorders.

Dr. Samantha DeCaro, specialized in eating disorders, cautions that today’s GLP-1 medications could be more harmful than their predecessors because they interfere with a person’s natural hunger cues, making it more difficult to nourish themselves properly.

DeCaro recounts the case of a patient with an extremely low BMI of 16 who was taking a GLP-1 medication, highlighting the dangers of misusing these drugs. “It’s crucial to ensure patients are aware of how these medications interact with their unique conditions,” she insists.

Challenges with Recognition

Particularly concerning is the risk for those with “atypical anorexia,” individuals who meet anorexia criteria but aren’t underweight. These patients may be misdiagnosed, leading to inappropriate prescriptions for GLP-1s.

Krynicki’s Path Forward

Krynicki acknowledges the complexities of living with obesity while battling anorexia. The stigma surrounding men with eating disorders made it difficult for him to confront and discuss his challenges. “Men are told to suppress their emotions,” he points out.

Fortunately, Krynicki has found supportive friendships within the obesity care community, which encourage him to maintain healthy eating habits. “Without my friends, I might not be here today,” he reflects, recognizing the vital role of his social circle in his recovery.

This support has become a crucial element in his journey toward understanding and managing his health.